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ABSTRACT
Immunization with the tetanus, diphtheria, and pertussis (Tdap) vaccine raises controversies on
immunogenicity and possible antibody interference. We performed an experimental, double-blind,
parallel group controlled clinical trial to evaluate the safety and immunogenicity of the Tdap vaccine in
204 pregnant women and their children and to determine its interference in antibody production.
Pregnant women 18 to 38 y of age with 12 to 24 weeks gestation, a low obstetric risk, and without serious
disease were randomly selected. The experimental group received 0.5 mL IM of Tdap and the control
group normal saline. Six blood samples were drawn before and after solution application, and from the
umbilical cord of the infants and at 2, 4, and 6 months of age. Pertactin and Pertussis toxin antibodies and
possible interference of maternal antibodies with the vaccine were determined.
In the experimental group, antibodies against Bordetella pertussis pertactin (anti-PRN) (112 E/mL 95% CI
89.9–139.9) and antibodies against pertussis toxin (anti-PT) (24.0 E/mL, 95% CI 18.3–31.4) were elevated in
the mother before vaccination. These were higher in the umbilical cord and descended in the infant at
2 months (71.4 (95% CI 56.8–89.7 and 10.9; 95% CI 8.7–13.7, respectively). Anti-PT showed a delay in
production. Tdap safety was conﬁrmed with only mild local pain at 24 and 48 hours.
Anti-PRN and anti-PT antibodies in the infant descend at 2 months of age. There is a delay in anti-PT in
children of immunized mothers. Further studies are needed to elucidate its clinical signiﬁcance.
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Introduction
Pertussis is a signiﬁcant cause of infant mortality worldwide,
despite high vaccine coverage.1 In Mexico, the pentavalent acel-
lular vaccine (DPaT/VIPCHib) is administered at 2, 4, 6 and
18 months of age, and a diphtheria, pertussis and tetanus
(DPT) booster is administered at 4 y.2 Very good coverage has
been achieved–up to 90.2% nationally and up to 91.8% in the
state of Nuevo Leon.3 Despite this, in September 2015, 113
cases of whooping cough were reported in Nuevo Leon.4
Pertussis related incidence and mortality occurs more fre-
quently in children under 3 months, as during an epidemic in
California in 2010.5
An explanation for this may be transplacental loss of anti-
bodies because of a decreased titer of maternal antibodies over
time6 and the rapid decomposition of antibodies in the infant
after approximately 2 months of age.7
In a study of blood samples from pregnant women and umbili-
cal cords performed in Nuevo Leon, no protective titers were
obtained.8 In another study—part of phase I of this project
—immunoglobulin G (IgG) was found in only 4.3% of umbilical
cord blood samples, 1.4% from themother and 0% from the child.6
The epidemiology of the disease has changed with adoles-
cents and adults acting as reservoirs. In Mexico City, 32.8% of
adolescents who had a cough for more than 14 d tested positive
for pertussis, with the potential to transmit the disease.9
In the face of this global epidemiological panorama, several
strategies have been implemented, including administering a
6th dose of the tetanus, diphtheria, and pertussis acellular
(Tdap) vaccine in adolescence10 and immunizing adolescents
and adults that live with newborns,11 although this latter strat-
egy is considered impractical and costly.12,13
Administering Tdap to pregnant women with the aim of
intensifying the transfer of antibodies to the child14,15 seems
appropriate ; however, there are reservations about its safety.16
In the United States, the Vaccine Adverse Event Reporting
System stated that no adverse events occurred in 42% (55) of
individuals who received Tdap immunization. The most com-
mon adverse event was reaction at the application site in 4.5%
(6).17 Similar ﬁndings were obtained in children born to
women who received this vaccine in the study by Shakib, et al.18
In Mexico, studies on the efﬁcacy and safety of acellular vac-
cines in pregnant women are nonexistent; therefore, the objec-
tive of this study is to evaluate the safety and immunogenicity
of the Tdap vaccine in pregnant women and their newborns up
to 6 months of age and assess the interference of the Tdap vac-
cine in pregnant women with the DPaT in their children.
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Materials and methods
Study design
This was randomized, double-blind, parallel group controlled
clinical trial.
Participants
The participants were pregnant women who sought pre-
natal care from September 2011 to August 2014 at 12
outpatient health centers of the Nuevo Leon Health Serv-
ices. The centers were within a speciﬁc geographical area
to ensure follow-up. The women were 18 to 38 y of age,
had a low obstetric risk, a normal anatomical ultrasound
in the second trimester of pregnancy, volunteered to par-
ticipate, and signed informed consent prior to inclusion
(Table 1).
Women who did not meet the inclusion criteria (7), suffered
a psychiatric disease (schizophrenia, psychosis, major depres-
sion) or a severe physical disease (diabetes mellitus, hyperten-
sion or degenerative diseases), consumed drugs or tobacco, had
a history of severe reactions to any vaccine or had had a febrile
illness in the 72 hours prior to vaccination were excluded.
Some women who had been immunized against tetanus and/or
pertussis in the 2 y prior to the study or who refused to partici-
pate were also excluded.
Additionally, women who developed any severe disease dur-
ing pregnancy, who had an abortion and those who were lost
to follow-up during pregnancy or whose child was lost to fol-
low-up were excluded (Fig. 1).
Ethical aspects
The project was approved by the Ethics Committee and the
Research Committee of a university hospital and registered at
clinical trials.gov with registration no. NCT01445743; URL:
https://clinicaltrials.gov/ct2/show/NCT01445743?termDTdapC
ANDCpregnancy&rankD2. The study subjects’ participation
was voluntary and their anonymity was protected. They also
received no compensation and signed a written informed consent.
Main outcomes and measures
The main results were immunogenicity and interference of
maternal antibodies. Patients were recruited and interviewed
by their doctors in the outpatient unit and then completed the
corresponding sections of the instrument. They were sent to a
hospital with obstetric care for 1) an abdominal ultrasound
examination to detect abnormalities (weeks 24–26) prior to the
extraction of the ﬁrst 5-cc blood sample; 2) the administration
of the Tdap vaccine or placebo between weeks 30 and 32 of ges-
tation by a trained nurse who was blinded to the procedure;
and 3) for delivery or Caesarian section and the collection of
the second blood sample at least 4 weeks after vaccine adminis-
tration and the third blood sample from the umbilical cord.
Home visits were conducted when the children were 2, 4, and
6 months of age, at which point the 4th, 5th and 6th blood sam-
ples were taken prior to the administration of the vaccines indi-
cated in the national vaccination schedule for Mexico, which
includes the pentavalent vaccine with the DTaP component
(Fig. 2).
Each blood sample tube was carefully labeled with the date,
hour and participant code and was taken directly to the labora-
tory for preservation at ¡70 Celsius until the procedure was
conducted.
To determine the level of antibodies against speciﬁc pertus-
sis antigens, a quantitative in vitro assay of human IgG antibod-
ies against Bordetella pertussis pertactin (PRN) and pertussis
toxin (PT) in serum was conducted using the anti-Bordetella
pertussis toxin ELISA (IgG) and the anti-Bordetella PRN
ELISA (IgG) (EUROIMMUN Medizinische Labordiagnostika
AG, Lubeck Germany) commercial kits according to the manu-
facturer’s instructions. The IgG levels in serum were reported
as optical densities, which were transformed to ELISA units
(EU) per milliliter.
To evaluate the safety of the vaccine, a trained nurse at the
hospital completed the record of adverse events at 30 minutes
after vaccination. Subsequent evaluations were performed 24
and 48 hours and one month after vaccination. Additional
information was recorded during postpartum and healthy child
check-ups and when the infant was 2, 4, and 6 months old.
Sampling and sample size
The sample size was determined with a power of 90% for effect
sizes of 0.50;19 86 observations per group were required. To
account for a nonresponse rate of 15%, a ﬁnal sample size of
204 with 102 in each group was obtained.
The selected pregnant women were randomly assigned to
one of the groups, vaccine or placebo. Randomization occurred
Table 1. Demographic and obstetrical data.
Experimental Control Total
Variable f % f % f %
School level
Primary 10 11.1 11 13.6 21 12.3
Secondary 51 56.7 59 72.8 110 64.3
Preparatory 23 25.6 9 11.1 32 18.7
University 3 3.3 2 2.5 5 2.9
Technical 3 3.3 0 0.0 3 1.8
Total 90 100.0 81 100.0 171 100.0
Marital status
Single 10 11.1 7 8.6 17 9.9
Married 32 35.6 21 25.9 53 31.0
Common law 47 52.2 52 64.2 99 57.9
Widow 1 1.1 0 0.0 1 0.6
Separated/divorced 0 0.0 1 1.2 1 0.6
Total 90 100.0 81 100.0 171 100.0
Occupation
Student 2 2.2 1 1.2 3 1.8
Worker 0 0.0 2 2.5 2 1.2
Employee 4 4.4 4 4.9 8 4.7
Housewife 83 92.2 74 91.4 157 91.7
Other 1 1.1 0 0.0 1 0.6
Total 90 100.0 81 100.0 171 100.0
Mean SD Mean SD
Age (years) 23.8 4.8 23.7 5.0
No. of pregnancies 2.2 1.2 2.3 1.1
No. of births 0.7 1.0 0.8 1.0
No. of cesarean sections 0.3 0.6 0.3 0.5
No. of abortions 0.2 0.5 0.1 0.4
No data were statistically signiﬁcant.
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using blocks of 2 repetitions of 2 groups (4 observations per
block); thus, 51 blocks were randomly selected for the 6 possi-
ble combinations.
Statistical methods
Descriptive statistics were calculated for the percentages and
frequencies of demographic data, maternal and child factors.
Safety outcome measures were described by frequency propor-
tion. The geometric mean concentration was determined to
evaluate antibody titers against PT and PRN and plotted using
95% CIs. Groups were compared using the Mann-Whitney test
for non-normal data distribution with a P < .05 being signiﬁ-
cant. An intention to treat analysis was not done because
responses from the primary outcome were missing.
The primary analysis of immunogenicity included participants
who received 2 injections (one vaccine and one saline placebo)
and contributed both pre- and post-vaccination blood samples
for testing. No imputation was carried out for missing data.
Results
There were 171 active participants, 90 in the experimental
group and 81 in the control group. For 113 participants, all 6 of
the required samples were collected. Of all 953 blood samples,
171 were collected from the pregnant women before adminis-
tration of the vaccine or placebo; 161 were collected one month
after application, 147 were collected from the umbilical cord,
and 162, 159 and 153 were collected from the children at 2, 4
and 6 months of age, respectively.
The days of collection of the 4th blood sample (correspond-
ing to the children’s 2nd month of age) ranged from 69.2
(SD 11.7) to 68.7 (SD 9.3); 5th sample (4th month) ranged from
128.7 (SD 14.1) to 129 (SD 13.3), and the 6th sample
(6th month) from 191.3 (SD 22.0) to 186.1 d (SD 14.7) in the
vaccine and control groups, respectively, with no signiﬁcant
difference.
The mothers mean age was 24.2 y (SD 5.0) in the experi-
mental group and 23.8 y (SD 5.0) in the control group. Most of
the participating women had a secondary school level, a marital
status of cohabiting and were housewives. There were no signif-
icant differences between the experimental and placebo groups
(Table 1). Most of the women had received pertussis vaccines
during childhood.
They denied a history of pertussis or being in contact with
someone diagnosed with or suspected of having pertussis dur-
ing the previous month.
Few adverse reactions after the application of the vaccine/
placebo occurred; local reactions predominated (Table 2).
The geometric means of IgG against PRN and PT for both
groups are shown in Table 3. A statistically signiﬁcant differ-
ence was observed in favor of the experimental group except
before vaccination. Fig. 3 shows the levels of IgG against PRN
for the 6 groups of blood samples collected from both the
experimental and the placebo groups. An increase in IgG in the
serum of the mothers 14 times greater than baseline was found;
this increase was even greater in cord serum although it subse-
quently decreased showing a cord:2-month old child serum
Table 2. Adverse reactions.
Experimental Control Total
Variable f % f % F %
30 minutes
None 90 100.0 81 100.0 171 100.0
TOTAL 90 100.0 81 100.0 171 100.0
24 hours
Headache 0 0.0 2 2.5 2 1.2
Local erythema 2 2.2 1 1.2 3 1.8
Local heat 1 1.1 0 0.0 1 0.6
Mild local pain 20 22.2 17 21.0 37 21.6
Nausea and/or vomiting 1 1.1 2 2.5 3 1.8
Fatigue 2 2.4 0 0.0 2 1.2
More than one symptom 11 12.1 3 3.7 14 8.1
None 53 58.9 56 69.1 109 63.7
TOTAL 90 100.0 81 100.0 171 100.0
48 hours
Mild local pain 7 7.8 5 6.2 12 7.0
Nausea and/or vomiting 0 0.0 1 1.2 1 0.6
Muscle pain 1 1.1 0 0.0 1 0.6
None 76 84.4 73 90.1 149 87.1
More than one symptom 6 6.7 2 2.5 8 4.7
TOTAL 90 100.0 81 100.0 171 100.0
1 month
None 90 100.0 81 100.0 171 100.0
TOTAL 90 100.0 81 100.0 171 100.0
No data were statistically signiﬁcant.
Table 3. Geometric means of antipertactin and antipertussis toxin antibodies in both groups.
Antipertactin Antibodies Antipertussis Toxin Antibodies
Treatment Var GM 95CI-L GM 95CI-U GM P GM 95CI-L GM 95CI-U GM P
Tdap MBV 8.53 6.71 10.85 0.908 5.93 4.55 7.74 0.138
Placebo MBV 8.08 6.11 10.68 7.90 5.92 10.54
Tdap MAV 112.08 89.79 139.91 0.001 24.04 18.39 31.43 0.001
Placebo MAV 7.16 5.38 9.53 7.06 5.24 9.50
Tdap CORD 127.51 104.15 156.12 0.001 28.25 21.06 37.90 0.001
Placebo CORD 8.07 5.84 11.14 8.02 5.84 11.00
Tdap CH2M 71.41 56.80 89.77 0.001 10.95 8.71 13.77 0.001
Placebo CH2M 6.93 5.52 8.72 6.20 4.96 7.73
Tdap CH4M 35.35 27.59 45.29 0.001 14.77 12.35 17.66 0.008
Placebo CH4M 5.07 4.15 6.19 20.45 16.71 25.03
Tdap CH6M 16.75 12.94 21.68 0.001 49.09 40.86 58.99 0.007
Placebo CH6M 4.51 3.80 5.35 69.13 59.10 80.87
VarD Variable; GM D Geometric mean; 95CI-L GM and 95CI-U GM D lower and upper limits of the 95% conﬁdence interval for the geometric mean; P D Mann-Whitney
test to compare Tdap vs placebo.
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Figure 1. CONSORT ﬂow diagram of the phases of of the study.
Figure 2. Flow diagram of the experimental procedure.
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ratio for PRN of 1.78. Fig. 4 shows the IgG versus PT levels for
all time points and conditions. The elevation of PT is less
marked in the serum of the mothers after vaccination. This
increase also occurred in cord serum descending to a cord:2-
month old child serum ratio of 2.5.
Discussion
The safety of the Tdap vaccine was demonstrated in the
Mexican population because at 30 minutes and one month after
application, no reaction was reported. Furthermore, at 24 and
48 hours after administration, 22.2% and 21.0% of the partici-
pants in the control group reported local mild pain; thus, these
reactions can be considered secondary to the vaccine applica-
tion technique and not to the action of the biologic.
A recent study in the United States showed similar results
with no reports of adverse events in pregnant women, the fetus
or newborns 17, and the safety of the vaccination was conﬁrmed
by the infants’ birth weight, Apgar scores and neonatal exami-
nation.20 Similar safety indicators were reported among in a
study cohort of 20,074 pregnant women in the United
Kingdom.21
Regarding the ﬁrst main outcome, the immunogenic capac-
ity of the Tdap vaccine has already been demonstrated in babies
born to mothers who received the Tdap vaccine during preg-
nancy. These infants had a signiﬁcantly higher concentration of
antibodies against pertussis at birth and up to 2 months of age
compared with those whose mothers did not receive
vaccination.20
However, in this study, the vaccine produced an increase in
PRN and PT antibodies (especially PRN antibodies) in the
pregnant women, and these levels were elevated in the umbili-
cal cord. However, the proportion of antibodies that pass trans-
placentally to the newborn is much lower.
Speciﬁc transplacental transfer of IgG is so variable that it
ranges between 20% and 200%.22 The gestational age at which
the vaccine is applied can affect the titer, leading to a 6-fold
greater concentration (46 EI/mL) when the vaccine is adminis-
tered between weeks 27–30 § 6, according to Abu Raya et al.23
In the current study, the vaccine was administered between
weeks 28–30 of gestation, which could explain the increase in
postvaccine levels of Ig against PT and PRN in the mother
(112.0 EI/mL and 24.0 EI/mL, respectively). Therefore, the
Center for Disease Control and Prevention recommends Tdap
immunization during pregnancy, preferably at 27–36 weeks of
gestation.15 However, pregnant women showed greater produc-
tion of anti-PRN than anti-PT, which is consistent with results
of other authors,20,24 although antibodies were not completely
transferred to the newborn.
Anti-PRN levels declined sharply in infants until 6 months
with no response to the usual DTaP vaccine scheme. This is
important because it has been established that PRN plays an
important role in the opsonization of Bordetella.25
In this study, anti-pertussis Ig levels showed an abrupt
decrease at 2 months; however, in the absence of consensus, it
is unclear whether this decrease provides protection against
infection with B. pertussis.20 Thus, it is difﬁcult to know the
proportion of infants that is unprotected at birth26, although
some authors have established a cutoff of more than 5 EU for
PT and more than 10 EU for FHA and PRN. 27 However, in
the current investigation, anti PT Ig levels were greater in the
Tdap group of children than in the placebo group of children
at 2 months. It was also observed that antibodies against PT
increased as the number of DPaT doses increased (at 2, 4 and
6 months). Pasetti et al.28 reported that complete protection is
not achieved after 3 doses. This occurs after the ﬁrst booster
has been applied. Another study reported an effectivity of
95.6% (95% CI:89.7%–98.0%) after 3 doses.29
Since this study examined infants up to 6 months of age,
there were no data on the behavior of antibodies after that
time, although an increasing trend was observed. In a study
that included children up to 7 months of age under different
conditions, the concentration of anti-PT in the children showed
no signiﬁcant difference between groups.20
Figure 3. Antipertactin Antibodies in the Experimental and Placebo Groups. IgG
levels vs. pertactin in 6 collected blood samples from the experimental and pla-
cebo groups. MBV, mother before vaccination; MAV, mother after vaccination;
COR, umbilical cord; CH2M, child at 2 months of age; CH4M, child at 4 months of
age; CH6M, child at 6 months of age.
Figure 4. Antibodies against Pertussis Toxin in the Experimental and Placebo
Groups. IgG levels versus detoxiﬁed pertussis toxin in 6 collected blood samples.
Abbreviations: MBV, mother before vaccination; MAV, mother after vaccination;
COR, umbilical cord; CH2M, child at 2 months of age; CH4M, child at 4 months of
age; CH6M, child at 6 months of age.
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Regarding the second main outcome, there is apparently
some interference between maternal antibodies and the
endogenous production of anti-PT in response to the DTaP
vaccine, as there was a delay in the response at 4 and
6 weeks among the children of women in the experimental
group compared with children from the control group, in
contrast to ﬁndings by Mu~noz et al.20 Published evidence
indicates that maternal Ig inhibits antibodies generated by
the complete cellular vaccine but not by the acellular vacci-
ne.30,31However, some authors have demonstrated that the
high concentration of maternal antibodies is bound to spe-
ciﬁc epitopes of the vaccine, thus avoiding interaction with
the child’s B cells. A second booster immunization or the
administration of a toxoid formulation with new adjuvant
has been proposed to overcome this interference.32 None-
theless, in a recent contribution, Mu~noz et al. clariﬁed that
there is no signiﬁcant difference in titers after application
of the booster vaccine.20
In contrast, Quinn et al. (2014) recently mentioned a pro-
gressive loss of antigenicity in children who received 5 doses of
DTaP.33 More studies are needed on this topic.
Considerations regarding the intervention
Vaccination with Tdap during pregnancy has been shown to be
more effective than vaccinations given immediately postpartum.
As vaccination during pregnancy was not associated with any
safety problems in the mother or child, it appears to be a good
alternative to postpartum vaccination. The study was double
blind and the experimental group received the Tdap vaccine
(Sanoﬁ Pasteur; 0.5 mL) intramuscularly.16 The control group
received a placebo of 0.9% saline solution, which was adminis-
tered by the same route and in the same dose as the vaccine.
Limitations
In this research, only 2 out of 3 recommended antibodies
against B. pertussis—PRN and PT—were measured to deter-
mine immunogenicity because of technical accessibility prob-
lems which prevented measuring the other antigen as was
originally planned. However, anti-PT is considered representa-
tive of the vaccine’s immunogenicity.
The children were not followed up to determine whether
they later contracted whooping cough, which would be a solid
demonstration of the vaccine’s immunogenicity. Ig against
PRN decreased rapidly during the child’s 2nd month of life;
however, it is unknown whether these levels remained protec-
tive against the disease.
Future direction
While it is unclear whether the high incidence of whooping cough
in the population is caused by a loss of the immunogenic effect of
the current Tdap vaccine or whether there is an antigenic change in
the B. pertussis strain, it is necessary to demonstrate whether the
lower levels of antipertussis and anti-PRN Ig in children, especially
at 2 and 4 months of age, are sufﬁcient to protect them against this
disease before they begin to generate their own antibodies. In the
same sense, the effectiveness of early Tdap immunization in chil-
dren at 6 weeks of age should be investigated.
Conclusions
The children of mothers who were vaccinated with Tdap
experience delayed production of antipertussis antibodies
for up to 6 months. The vaccination of pregnant women
with Tdap generates antibodies in the mother that can be
lost within 2 months; however, Tdap vaccination appears to
be a feasible and safe strategy for providing their children
with antibodies against pertussis, although more studies are
needed to demonstrate whether this transfer of antibodies is
effective and timely.
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